References: 1. Gordon S, Barbacioru C, Liao J, et al. Prediction of cardiac adverse events (AE) in trastuzumab treated breast cancer patients (pts) via a comprehensive genomic and DNA methylation blood-based assay. Cancer Res. 2024;84(6_suppl):Abs 3399. Accessed March 19, 2025. https://doi.org/10.1158/1538-7445.AM2024-3399
2. Wienke S, Gordon S, Liang S et al. Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay. Cancer Res. 2024;84(6_suppl):Abs 2490. Accessed March 19, 2024. https://doi.org/10.1158/1538-7445.AM2024-2490 3. Rosen E, Schonhoft JD, Silverman IM, et al. Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (Guardant Infinity) for diagnosis of DNA damage repair (DOR) loss-of-function (LoF) and response monitoring in the TRESR and ATTACC trials. Mol Cancer Ther. 2023;22(12_suppl):A123. Accessed March 19, 2025. https://doi.org/10.1158/1535-7163.TARG-23-A123 4. Guardant Health data on file. 2025. Guardant Health, Inc. Redwood City, CA.